Can I take Trelegy (fluticasone furoate / umeclidinium / vilanterol) and Breztri (budesonide / glycopyrrolate / formoterol) together?

Can You Take Trelegy and Breztri Together?

No, you should not take Trelegy (fluticasone furoate/umeclidinium/vilanterol) and Breztri (budesonide/glycopyrrolate/formoterol) together, as both are triple-therapy inhalers containing the same classes of medications—an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA)—and using them concurrently would result in dangerous medication duplication and excessive dosing. 1

Why This Combination Is Contraindicated

Medication Class Overlap

• Both inhalers contain an inhaled corticosteroid: Trelegy contains fluticasone furoate while Breztri contains budesonide, and using both simultaneously would deliver double the intended corticosteroid dose, significantly increasing the risk of systemic corticosteroid effects including adrenal suppression, osteoporosis, cataracts, and immunosuppression. 2

• Both inhalers contain a LAMA: Trelegy contains umeclidinium while Breztri contains glycopyrrolate, and concurrent use would result in excessive anticholinergic effects including urinary retention, constipation, dry mouth, blurred vision, and potentially dangerous cardiovascular effects. 1

• Both inhalers contain a LABA: Trelegy contains vilanterol while Breztri contains formoterol, and using both would cause LABA overdose with risks of tachycardia, tremor, hypokalemia, QT prolongation, and potentially life-threatening arrhythmias. 3

Choosing Between Trelegy and Breztri

Evidence for Trelegy (FF/UMEC/VI)

• Trelegy demonstrated superior real-world effectiveness in a 2025 comparative study of 44,542 Medicare patients, showing a 12% lower rate of moderate-severe COPD exacerbations (0.80 vs 0.91 per patient-year; rate ratio 0.88,95% CI 0.85-0.92; P < 0.001) and an 11% lower risk of all-cause mortality at 12 months (HR 0.89,95% CI 0.80-0.98; P = 0.020) compared with Breztri. 4

• Once-daily dosing with Trelegy may improve adherence compared with Breztri's twice-daily regimen, which is clinically relevant given that medication adherence is a leading cause of poor COPD control. 5, 3

• Network meta-analysis data from 2022 showed Trelegy demonstrated statistically significant improvements in trough FEV1 and annualized exacerbation rates versus Breztri (budesonide/glycopyrrolate/formoterol). 6

Evidence for Breztri (BUD/GLY/FOR)

• A 2022 meta-analysis found no significant differences in exacerbation risk, lung function, dyspnea scores, quality of life, serious adverse events, cardiovascular events, pneumonia risk, or all-cause mortality between the triple FDCs when analyzed across 21,809 patients. 7

• Breztri contains formoterol, which has a rapid onset of action and could theoretically provide faster symptom relief than vilanterol, though this has not been demonstrated to translate into clinically meaningful differences in real-world outcomes. 8

Clinical Recommendation Algorithm

For most COPD patients requiring triple therapy, initiate Trelegy (FF/UMEC/VI 100/62.5/25 mcg once daily) as the preferred option based on:

1. Superior real-world effectiveness in reducing exacerbations and mortality 4
2. Once-daily dosing improving adherence 5
3. Robust evidence from the IMPACT trial showing greater efficacy versus dual therapies 5

Consider Breztri (BUD/GLY/FOR 160/9/4.8 mcg twice daily) only if:

1. Patient has documented intolerance or contraindication to fluticasone furoate 7
2. Patient specifically requires twice-daily dosing for adherence reasons (e.g., established routine with other twice-daily medications) 1
3. Insurance formulary restrictions mandate Breztri use 7

Common Pitfalls to Avoid

• Never prescribe both triple-therapy inhalers simultaneously under any circumstances, as this represents dangerous polypharmacy with no clinical benefit and substantial harm potential. 1, 2

• Do not add a short-acting muscarinic antagonist (such as ipratropium or DuoNeb) to either triple-therapy regimen, as the LAMA component already provides long-acting anticholinergic coverage and additional anticholinergic therapy is contraindicated. 3

• Avoid switching between triple therapies without a clear clinical rationale, as both are effective and switching may confuse patients and disrupt adherence without improving outcomes. 7

• Monitor for pneumonia risk with either ICS-containing regimen, particularly in older adults and those with prior pneumonia history, as ICS therapy increases pneumonia incidence with an odds ratio of 1.38-1.48. 2